RxDoctor Payments Data

Christopher Rumsey, DO

Obstetrics & Gynecology · Bangor, MENPI 1356548168

Payments from drug & device makers

What this record shows

This record is dominated by education: $5,838 of the $9,537 with a category attached, or 61.2%. Intuitive Surgical accounts for 85.6% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $8,180, more than ten times the $50 reported in 2020. Among obstetrics & gynecology clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,537in general payments, 2019–2025

Across 44 payments — averaging $216.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • Axonics, Inc.$838
  • Astellas Pharma US Inc$353
  • Bayer$50
  • Pfizer$46
  • Daiichi Sankyo Inc.$30
  • plus $54 from 2 others

What the payments were for

  • Travel & lodging$3,18433%
  • Food & beverage$5155%
  • Education$5,83861%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,537 in reported general payments places this provider in the 95th percentile of 162 obstetrics & gynecology providers in Maine.

See all obstetrics & gynecology providers in Maine

Medicare billing

Part B allowed, 2024
$20,223
Medicare patients
105
Services billed
239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron13$8,502
Estradiol19$476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$353$8,50213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 162 obstetrics & gynecology providers in Maine.

Other obstetrics & gynecology in Bangor

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →